Preclinical COPD Models | Rodent & Guinea Pig Studies

Preclinical COPD Models for Respiratory Drug Development

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterized by persistent airflow limitation, airway inflammation, mucus hypersecretion, small-airway remodeling, and emphysema-associated destruction of alveolar architecture.

IPS Therapeutique offers preclinical COPD models in mice, rats, and guinea pigs using elastase, LPS, cigarette smoke exposure, or combined approaches to reproduce key features of human COPD. These models support the evaluation of anti-inflammatory, bronchodilator, mucus-modulating, anti-remodeling, and lung-protective therapies.

Integrated readouts include lung function, BALF inflammatory cell counts, cytokine and chemokine analysis, and histological assessment of emphysema, airway inflammation, and tissue remodeling.

Chronic Obstructive Pulmonary Disease.jpg

COPD Model Methodology

Available COPD model options include:
Species: mouse, rat, and guinea pig
Induction methods: elastase, LPS, cigarette smoke exposure, or combination protocols
Disease features: airway inflammation, mucus hypersecretion, emphysema, airspace enlargement, and lung function impairment
Study duration: short-term inflammatory models to longer COPD-like disease models
Treatment designs: preventive, interventional, or therapeutic dosing paradigms

COPD Model Readouts and Drug Development Applications

Typical COPD model readouts include:

Lung function: plethysmography, respiratory pattern analysis, pulmonary pressure-volume loop analysis
BALF analysis: total and differential inflammatory cell counts, including neutrophils and macrophages
Biochemical markers: cytokines, chemokines, inflammatory mediators, and tissue injury markers
Histology: H&E assessment of airway inflammation, emphysema, alveolar destruction, and remodeling
Morphometry: airspace enlargement and emphysema-related structural changes

Application:

By replicating human COPD characteristics, these models provide a robust platform for preclinical evaluation, helping to identify and optimize potential treatments before clinical trials, enabling the assessment of novel therapeutics targeting inflammation, mucus production, and lung tissue destruction.